Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “PHASE SPACE”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,351 records · Page 75
All sourcesNASA NTRSDOE OSTI
DOE OSTI2014

Milky Way mass and potential recovery using tidal streams in a realistic halo

We present a new method for determining the Galactic gravitational potential based on forward modeling of tidal stellar streams. We use this method to test the performance of smooth and static analytic potentials in representing realistic dark matter halos, which have substructure and are continually evolving by accretion. Our FAST-FORWARD method uses a Markov Chain Monte Carlo algorithm to compare, in six-dimensional phase space, an 'observed' stream to models created in trial analytic potentials. We analyze a large sample of streams that evolved in the Via Lactea II (VL2) simulation, which represents a realistic Galactic halo potential. The recovered potential parameters are in agreement with the best fit to the global, present-day VL2 potential. However, merely assuming an analytic potential limits the dark matter halo mass measurement to an accuracy of 5%-20%, depending on the choice of analytic parameterization. Collectively, the mass estimates using streams from our sample reach this fundamental limit, but individually they can be highly biased. Individual streams can both under- and overestimate the mass, and the bias is progressively worse for those with smaller perigalacticons, motivating the search for tidal streams at galactocentric distances larger than 70 kpc. We estimate that the assumption of a static and smooth dark matter potential in modeling of the GD-1- and Pal5-like streams introduces an error of up to 50% in the Milky Way mass estimates.

79 ASTRONOMY AND ASTROPHYSICS↗
DOE OSTI2013

Anisotropic dark matter distribution functions and impact on WIMP direct detection

Dark matter N-body simulations suggest that the velocity distribution of dark matter is anisotropic. In this work we employ a mass model for the Milky Way whose parameters are determined from a fit to kinematical data. Then we adopt an ansatz for the dark matter phase space distribution which allows to construct self-consistent halo models which feature a degree of anisotropy as a function of the radius such as suggested by the simulations. The resulting velocity distributions are then used for an analysis of current data from dark matter direct detection experiments. We find that velocity distributions which are radially biased at large galactocentric distances (up to the virial radius) lead to an increased high velocity tail of the local dark matter distribution. This affects the interpretation of data from direct detection experiments, especially for dark matter masses around 10 GeV, since in this region the high velocity tail is sampled. We find that the allowed regions in the dark matter mass-cross section plane as indicated by possible hints for a dark matter signal reported by several experiments as well as conflicting exclusion limits from other experiments shift in a similar way when the halo model is varied. Hence, it is not possible to improve the consistency of the data by referring to anisotropic halo models of the type considered in this work.

79 ASTRONOMY AND ASTROPHYSICS↗
DOE OSTI2015

TU-G-BRB-00: Clinical Trials in Proton and Particle Therapy

Proton therapy, in particular, and ion therapy, just beginning, are becoming an increasing focus of attention in clinical radiation oncology and medical physics. Both modalities have been criticized of lacking convincing evidence from randomized trials proving their efficacy, justifying the higher costs involved in these therapies. This session will provide an overview of the current status of clinical trials in proton therapy, including recent developments in ion therapy. As alluded to in the introductory talk by Dr. Schulte, opinions are diverging widely as to the usefulness and need for clinical trials in particle therapy and the challenge of equipoise. The lectures will highlight some of the challenges that surround clinical trials in particle therapy. One, presented by Dr. Choy from UT Southwestern, is that new technology and even different types of particles such as helium and carbon ions are introduced into this environment, increasing the phase space of clinical variables. The other is the issue of medical physics quality assurance with physical phantoms, presented by Mrs. Taylor from IROC Houston, which is more challenging because 3D and 4D image guidance and active delivery techniques are in relatively early stages of development. The role of digital phantoms in developing clinical treatment planning protocols and as a QA tool will also be highlighted by Dr. Lee from NCI. The symposium will be rounded off by a panel discussion among the Symposium speakers, arguing pro or con the need and readiness for clinical trials in proton and ion therapy. Learning Objectives: To get an update on the current status of clinical trials allowing or mandating proton therapy. Learn about the status of planned clinical trials in the U.S. and worldwide involving ion therapy. Discuss the challenges in the design and QA of clinical trials in particle therapy. Learn about existing and future physical and computational anthropomorphic phantoms for charged particle clinical trial development and support. Research reported in this presentation is supported by the National Cancer Institute of the National; Institutes of Health under Award Number P20CA183640.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2013

Interacting warm dark matter

We explore a cosmological model composed by a dark matter fluid interacting with a dark energy fluid. The interaction term has the non-linear λρ{sub m}{sup α}ρ{sub e}{sup β} form, where ρ{sub m} and ρ{sub e} are the energy densities of the dark matter and dark energy, respectively. The parameters α and β are in principle not constrained to take any particular values, and were estimated from observations. We perform an analytical study of the evolution equations, finding the fixed points and their stability properties in order to characterize suitable physical regions in the phase space of the dark matter and dark energy densities. The constants (λ,α,β) as well as w{sub m} and w{sub e} of the EoS of dark matter and dark energy respectively, were estimated using the cosmological observations of the type Ia supernovae and the Hubble expansion rate H(z) data sets. We find that the best estimated values for the free parameters of the model correspond to a warm dark matter interacting with a phantom dark energy component, with a well goodness-of-fit to data. However, using the Bayesian Information Criterion (BIC) we find that this model is overcame by a warm dark matter – phantom dark energy model without interaction, as well as by the ΛCDM model. We find also a large dispersion on the best estimated values of the (λ,α,β) parameters, so even if we are not able to set strong constraints on their values, given the goodness-of-fit to data of the model, we find that a large variety of theirs values are well compatible with the observational data used.

79 ASTRONOMY AND ASTROPHYSICS↗
DOE OSTI2015

SU-E-T-157: CARMEN: A MatLab-Based Research Platform for Monte Carlo Treatment Planning (MCTP) and Customized System for Planning Evaluation

Purpose: Although there exist several radiotherapy research platforms, such as: CERR, the most widely used and referenced; SlicerRT, which allows treatment plan comparison from various sources; and MMCTP, a full MCTP system; it is still needed a full MCTP toolset that provides users complete control of calculation grids, interpolation methods and filters in order to “fairly” compare results from different TPSs, supporting verification with experimental measurements. Methods: This work presents CARMEN, a MatLab-based platform including multicore and GPGPU accelerated functions for loading RT data; designing treatment plans; and evaluating dose matrices and experimental data.CARMEN supports anatomic and functional imaging in DICOM format, as well as RTSTRUCT, RTPLAN and RTDOSE. Besides, it contains numerous tools to accomplish the MCTP process, managing egs4phant and phase space files.CARMEN planning mode assist in designing IMRT, VMAT and MERT treatments via both inverse and direct optimization. The evaluation mode contains a comprehensive toolset (e.g. 2D/3D gamma evaluation, difference matrices, profiles, DVH, etc.) to compare datasets from commercial TPS, MC simulations (i.e. 3ddose) and radiochromic film in a user-controlled manner. Results: CARMEN has been validated against commercial RTPs and well-established evaluation tools, showing coherent behavior of its multiple algorithms. Furthermore, CARMEN platform has been used to generate competitive complex treatment that has been published in comparative studies. Conclusion: A new research oriented MCTP platform with a customized validation toolset has been presented. Despite of being coded with a high-level programming language, CARMEN is agile due to the use of parallel algorithms. The wide-spread use of MatLab provides straightforward access to CARMEN’s algorithms to most researchers. Similarly, our platform can benefit from the MatLab community scientific developments as filters, registration algorithms etc. Finally, CARMEN arises the importance of grid and filtering control in treatment plan comparison.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2015

TU-G-BRB-01: Topic Introduction: Do We Need Clinical Trials in Particle Therapy and How Can Medical Physics Support Them?

Proton therapy, in particular, and ion therapy, just beginning, are becoming an increasing focus of attention in clinical radiation oncology and medical physics. Both modalities have been criticized of lacking convincing evidence from randomized trials proving their efficacy, justifying the higher costs involved in these therapies. This session will provide an overview of the current status of clinical trials in proton therapy, including recent developments in ion therapy. As alluded to in the introductory talk by Dr. Schulte, opinions are diverging widely as to the usefulness and need for clinical trials in particle therapy and the challenge of equipoise. The lectures will highlight some of the challenges that surround clinical trials in particle therapy. One, presented by Dr. Choy from UT Southwestern, is that new technology and even different types of particles such as helium and carbon ions are introduced into this environment, increasing the phase space of clinical variables. The other is the issue of medical physics quality assurance with physical phantoms, presented by Mrs. Taylor from IROC Houston, which is more challenging because 3D and 4D image guidance and active delivery techniques are in relatively early stages of development. The role of digital phantoms in developing clinical treatment planning protocols and as a QA tool will also be highlighted by Dr. Lee from NCI. The symposium will be rounded off by a panel discussion among the Symposium speakers, arguing pro or con the need and readiness for clinical trials in proton and ion therapy. Learning Objectives: To get an update on the current status of clinical trials allowing or mandating proton therapy. Learn about the status of planned clinical trials in the U.S. and worldwide involving ion therapy. Discuss the challenges in the design and QA of clinical trials in particle therapy. Learn about existing and future physical and computational anthropomorphic phantoms for charged particle clinical trial development and support. Research reported in this presentation is supported by the National Cancer Institute of the National; Institutes of Health under Award Number P20CA183640.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2015

TU-G-BRB-02: Clinical Trials in Particle Therapy - Open Questions

Proton therapy, in particular, and ion therapy, just beginning, are becoming an increasing focus of attention in clinical radiation oncology and medical physics. Both modalities have been criticized of lacking convincing evidence from randomized trials proving their efficacy, justifying the higher costs involved in these therapies. This session will provide an overview of the current status of clinical trials in proton therapy, including recent developments in ion therapy. As alluded to in the introductory talk by Dr. Schulte, opinions are diverging widely as to the usefulness and need for clinical trials in particle therapy and the challenge of equipoise. The lectures will highlight some of the challenges that surround clinical trials in particle therapy. One, presented by Dr. Choy from UT Southwestern, is that new technology and even different types of particles such as helium and carbon ions are introduced into this environment, increasing the phase space of clinical variables. The other is the issue of medical physics quality assurance with physical phantoms, presented by Mrs. Taylor from IROC Houston, which is more challenging because 3D and 4D image guidance and active delivery techniques are in relatively early stages of development. The role of digital phantoms in developing clinical treatment planning protocols and as a QA tool will also be highlighted by Dr. Lee from NCI. The symposium will be rounded off by a panel discussion among the Symposium speakers, arguing pro or con the need and readiness for clinical trials in proton and ion therapy. Learning Objectives: To get an update on the current status of clinical trials allowing or mandating proton therapy. Learn about the status of planned clinical trials in the U.S. and worldwide involving ion therapy. Discuss the challenges in the design and QA of clinical trials in particle therapy. Learn about existing and future physical and computational anthropomorphic phantoms for charged particle clinical trial development and support. Research reported in this presentation is supported by the National Cancer Institute of the National; Institutes of Health under Award Number P20CA183640.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2015

TU-G-BRB-03: IROC Houston’s Proton Beam Validation for Clinical Trials

Proton therapy, in particular, and ion therapy, just beginning, are becoming an increasing focus of attention in clinical radiation oncology and medical physics. Both modalities have been criticized of lacking convincing evidence from randomized trials proving their efficacy, justifying the higher costs involved in these therapies. This session will provide an overview of the current status of clinical trials in proton therapy, including recent developments in ion therapy. As alluded to in the introductory talk by Dr. Schulte, opinions are diverging widely as to the usefulness and need for clinical trials in particle therapy and the challenge of equipoise. The lectures will highlight some of the challenges that surround clinical trials in particle therapy. One, presented by Dr. Choy from UT Southwestern, is that new technology and even different types of particles such as helium and carbon ions are introduced into this environment, increasing the phase space of clinical variables. The other is the issue of medical physics quality assurance with physical phantoms, presented by Mrs. Taylor from IROC Houston, which is more challenging because 3D and 4D image guidance and active delivery techniques are in relatively early stages of development. The role of digital phantoms in developing clinical treatment planning protocols and as a QA tool will also be highlighted by Dr. Lee from NCI. The symposium will be rounded off by a panel discussion among the Symposium speakers, arguing pro or con the need and readiness for clinical trials in proton and ion therapy. Learning Objectives: To get an update on the current status of clinical trials allowing or mandating proton therapy. Learn about the status of planned clinical trials in the U.S. and worldwide involving ion therapy. Discuss the challenges in the design and QA of clinical trials in particle therapy. Learn about existing and future physical and computational anthropomorphic phantoms for charged particle clinical trial development and support. Research reported in this presentation is supported by the National Cancer Institute of the National; Institutes of Health under Award Number P20CA183640.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2015

TU-G-BRB-04: Digital Phantoms for Developing Protocols in Particle Therapy

Proton therapy, in particular, and ion therapy, just beginning, are becoming an increasing focus of attention in clinical radiation oncology and medical physics. Both modalities have been criticized of lacking convincing evidence from randomized trials proving their efficacy, justifying the higher costs involved in these therapies. This session will provide an overview of the current status of clinical trials in proton therapy, including recent developments in ion therapy. As alluded to in the introductory talk by Dr. Schulte, opinions are diverging widely as to the usefulness and need for clinical trials in particle therapy and the challenge of equipoise. The lectures will highlight some of the challenges that surround clinical trials in particle therapy. One, presented by Dr. Choy from UT Southwestern, is that new technology and even different types of particles such as helium and carbon ions are introduced into this environment, increasing the phase space of clinical variables. The other is the issue of medical physics quality assurance with physical phantoms, presented by Mrs. Taylor from IROC Houston, which is more challenging because 3D and 4D image guidance and active delivery techniques are in relatively early stages of development. The role of digital phantoms in developing clinical treatment planning protocols and as a QA tool will also be highlighted by Dr. Lee from NCI. The symposium will be rounded off by a panel discussion among the Symposium speakers, arguing pro or con the need and readiness for clinical trials in proton and ion therapy. Learning Objectives: To get an update on the current status of clinical trials allowing or mandating proton therapy. Learn about the status of planned clinical trials in the U.S. and worldwide involving ion therapy. Discuss the challenges in the design and QA of clinical trials in particle therapy. Learn about existing and future physical and computational anthropomorphic phantoms for charged particle clinical trial development and support. Research reported in this presentation is supported by the National Cancer Institute of the National; Institutes of Health under Award Number P20CA183640.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2015

TU-G-BRB-05: Panel Discussion: Clinical Trials in Proton and Ion Therapy - Are We Ready?

Proton therapy, in particular, and ion therapy, just beginning, are becoming an increasing focus of attention in clinical radiation oncology and medical physics. Both modalities have been criticized of lacking convincing evidence from randomized trials proving their efficacy, justifying the higher costs involved in these therapies. This session will provide an overview of the current status of clinical trials in proton therapy, including recent developments in ion therapy. As alluded to in the introductory talk by Dr. Schulte, opinions are diverging widely as to the usefulness and need for clinical trials in particle therapy and the challenge of equipoise. The lectures will highlight some of the challenges that surround clinical trials in particle therapy. One, presented by Dr. Choy from UT Southwestern, is that new technology and even different types of particles such as helium and carbon ions are introduced into this environment, increasing the phase space of clinical variables. The other is the issue of medical physics quality assurance with physical phantoms, presented by Mrs. Taylor from IROC Houston, which is more challenging because 3D and 4D image guidance and active delivery techniques are in relatively early stages of development. The role of digital phantoms in developing clinical treatment planning protocols and as a QA tool will also be highlighted by Dr. Lee from NCI. The symposium will be rounded off by a panel discussion among the Symposium speakers, arguing pro or con the need and readiness for clinical trials in proton and ion therapy. Learning Objectives: To get an update on the current status of clinical trials allowing or mandating proton therapy. Learn about the status of planned clinical trials in the U.S. and worldwide involving ion therapy. Discuss the challenges in the design and QA of clinical trials in particle therapy. Learn about existing and future physical and computational anthropomorphic phantoms for charged particle clinical trial development and support. Research reported in this presentation is supported by the National Cancer Institute of the National; Institutes of Health under Award Number P20CA183640.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2016

Discovery of a metal-poor field giant with a globular cluster second-generation abundance pattern

We report on the detection, from observations obtained with the Apache Point Observatory Galactic Evolution Experiment spectroscopic survey, of a metal-poor ([Fe/H] = −1.3 dex) field giant star with an extreme Mg–Al abundance ratio ([Mg/Fe] = −0.31 dex; [Al/Fe] = 1.49 dex). Such low Mg/Al ratios are seen only among the second-generation population of globular clusters (GCs) and are not present among Galactic disk field stars. The light-element abundances of this star, 2M16011638-1201525, suggest that it could have been born in a GC. We explore several origin scenarios, studying the orbit of the star in particular to check the probability of its being kinematically related to known GCs. We performed simple orbital integrations assuming the estimated distance of 2M16011638-1201525 and the available six-dimensional phase-space coordinates of 63 GCs, looking for close encounters in the past with a minimum distance approach within the tidal radius of each cluster. We found a very low probability that 2M16011638-1201525 was ejected from most GCs; however, we note that the best progenitor candidate to host this star is GC ω Centauri (NGC 5139). Our dynamical investigation demonstrates that 2M16011638-1201525 reaches a distance |Z{sub max}|<3 kpc from the Galactic plane and minimum and maximum approaches to the Galactic center of R {sub min} < 0.62 kpc and R {sub max} < 7.26 kpc in an eccentric (e ∼ 0.53) and retrograde orbit. Since the extreme chemical anomaly of 2M16011638-1201525 has also been observed in halo field stars, this object could also be considered a halo contaminant, likely to have been ejected into the Milky Way disk from the halo. We conclude that 2M16011638-20152 is also kinematically consistent with the disk but chemically consistent with halo field stars.

79 ASTRONOMY AND ASTROPHYSICS↗
DOE OSTI2016

Oscillatory reaction cross sections caused by normal mode sampling in quasiclassical trajectory calculations

The quasiclassical trajectory (QCT) method is an efficient and important tool for studying the dynamics of bimolecular reactions. In this method, the motion of the atoms is simulated classically, and the only quantum effect considered is that the initial vibrational states of reactant molecules are semiclassically quantized. A sensible expectation is that the initial ensemble of classical molecular states generated this way should be stationary, similarly to the quantum state it is supposed to represent. The most widely used method for sampling the vibrational phase space of polyatomic molecules is based on the normal mode approximation. In the present work, it is demonstrated that normal mode sampling provides a nonstationary ensemble even for a simple molecule like methane, because real potential energy surfaces are anharmonic in the reactant domain. The consequences were investigated for reaction CH{sub 4} + H → CH{sub 3} + H{sub 2} and its various isotopologs and were found to be dramatic. Reaction probabilities and cross sections obtained from QCT calculations oscillate periodically as a function of the initial distance of the colliding partners and the excitation functions are erratic. The reason is that in the nonstationary ensemble of initial states, the mean bond length of the breaking C–H bond oscillates in time with the frequency of the symmetric stretch mode. We propose a simple method, one-period averaging, in which reactivity parameters are calculated by averaging over an entire period of the mean C–H bond length oscillation, which removes the observed artifacts and provides the physically most reasonable reaction probabilities and cross sections when the initial conditions for QCT calculations are generated by normal mode sampling.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
DOE OSTI2016

SU-F-T-81: Treating Nose Skin Using Energy and Intensity Modulated Electron Beams with Monte Carlo Based Dose Calculation

Purpose: Treating nose skin with an electron beam is of a substantial challenge due to uneven nose surfaces and tissue heterogeneity, and consequently could have a great uncertainty of dose accuracy on the target. This work explored the method using Monte Carlo (MC)-based energy and intensity modulated electron radiotherapy (MERT), which would be delivered with a photon MLC in a standard medical linac (Artiste). Methods: The traditional treatment on the nose skin involves the usage of a bolus, often with a single energy electron beam. This work avoided using the bolus, and utilized mixed energies of electron beams. An in-house developed Monte Carlo (MC)-based dose calculation/optimization planning system was employed for treatment planning. Phase space data (6, 9, 12 and 15 MeV) were used as an input source for MC dose calculations for the linac. To reduce the scatter-caused penumbra, a short SSD (61 cm) was used. A clinical case of the nose skin, which was previously treated with a single 9 MeV electron beam, was replanned with the MERT method. The resultant dose distributions were compared with the plan previously clinically used. The dose volume histogram of the MERT plan is calculated to examine the coverage of the planning target volume (PTV) and critical structure doses. Results: The target coverage and conformality in the MERT plan are improved as compared to the conventional plan. The MERT can provide more sufficient target coverage and less normal tissue dose underneath the nose skin. Conclusion: Compared to the conventional treatment technique, using MERT for the nose skin treatment has shown the dosimetric advantages in the PTV coverage and conformality. In addition, this technique eliminates the necessity of the cutout and bolus, which makes the treatment more efficient and accurate.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2014

SU-E-T-605: A New Design for a Rotating Gamma Knife. Monte Carlo Simulation

Purpose: to determine the characteristics of the 60Co beam emerging from a new design of a rotating Gamma Knife system and to calculate 3D dose distributions at the isocenter for different source configurations and collimator openings. Methods: We employed the BEAM-Monte Carlo code to realistically model the geometry design, including 30 60Co source capsules, two circular primary collimators (diameter of 6.6mm and 6.1mm) and four different changeable collimators. The shielding of the head design was also simulated. The sources (2.8mm diameter) are distributed in six groups in the spherical geometry. Each source is individually collimated to obtained four different circular fields at the isocenter (3mm, 3.5mm, 6mm and 8mm).The phase-space particles reaching the scoring plane below the primary collimation assembly were recorded and the BEAMDP code was used to determine the fluence and energy spectra of the particles emerging from each source-collimator configuration. The dose distributions at the isocenter plane (397.6mm from the source) were calculated in a spherical component module for the circular field sizes studied. Results: The energy spectra below the head assembly and primary collimators have been obtained, which exhibited the typical 60Co peaks and a small low-energy tail due to scattered photons (from about 200keV to 1MeV). The scattered component of the spectra represents about 8 % of the total number of photons reaching the scoring plane. The radial photon fluence does not vary significantly inside the collimator openings. The spectra of particles from different source groups are compared. Conclusion: The 60Co beam emerging from each source configuration was characterized, which can be used to establish a generic source model for all the sources for fast MC dose calculation. Further investigations are needed to determine the dose variations as a result of partial switching on/off different groups of sources for advanced Gamma Knife SRS/SBRT planning.

07 ISOTOPE AND RADIATION SOURCES↗
DOE OSTI2015

New signatures of the Milky Way formation in the local halo and inner-halo streamers in the era of Gaia

We explore the vicinity of the Milky Way through the use of spectrophotometric data from the Sloan Digital Sky Survey and high-quality proper motions derived from multi-epoch positions extracted from the Guide Star Catalog II database. In order to identify and characterize streams as relics of the Milky Way formation, we start with classifying, selecting, and studying 2417 subdwarfs with [Fe/H] < −1.5 up to 3 kpc away from the Sun as tracers of the local halo system. Then, through phase-space analysis, we find statistical evidence of five discrete kinematic overdensities among 67 of the fastest-moving stars and compare them to high-resolution N-body simulations of the interaction between a Milky Way–like galaxy and orbiting dwarf galaxies with four representative cases of merging histories. The observed overdensities can be interpreted as fossil substructures consisting of streamers torn from their progenitors; such progenitors appear to be satellites on prograde and retrograde orbits on different inclinations. In particular, of the five detected overdensities, two appear to be associated, yielding 21 additional main-sequence members, with the stream of Helmi et al. that our analysis confirms is on a high-inclination prograde orbit. The three newly identified kinematic groups could be associated with the retrograde streams detected by Dinescu and Kepley et al.; whatever their origin, the progenitor(s) would be on retrograde orbit(s) and inclination(s) within the range 10{sup ∘}÷60{sup ∘}. Finally, we use our simulations to investigate the impact of observational errors and compare the current picture to the promising prospect of highly improved data expected from the Gaia mission.

79 ASTRONOMY AND ASTROPHYSICS↗
DOE OSTI2013

Quantization maps, algebra representation, and non-commutative Fourier transform for Lie groups

The phase space given by the cotangent bundle of a Lie group appears in the context of several models for physical systems. A representation for the quantum system in terms of non-commutative functions on the (dual) Lie algebra, and a generalized notion of (non-commutative) Fourier transform, different from standard harmonic analysis, has been recently developed, and found several applications, especially in the quantum gravity literature. We show that this algebra representation can be defined on the sole basis of a quantization map of the classical Poisson algebra, and identify the conditions for its existence. In particular, the corresponding non-commutative star-product carried by this representation is obtained directly from the quantization map via deformation quantization. We then clarify under which conditions a unitary intertwiner between such algebra representation and the usual group representation can be constructed giving rise to the non-commutative plane waves and consequently, the non-commutative Fourier transform. The compact groups U(1) and SU(2) are considered for different choices of quantization maps, such as the symmetric and the Duflo map, and we exhibit the corresponding star-products, algebra representations, and non-commutative plane waves.

71 CLASSICAL AND QUANTUM MECHANICS, GENERAL PHYSIC↗
DOE OSTI2014

SU-E-T-237: Monte Carlo Dosimetric Characterization of the Mobetron Mobile Linac

Purpose: The aim of this work is to characterize dosimetrically a clinical intraoperative electron beam accelerator, Mobetron (IntraOp Medical, Inc.) in clinical use in our Hospital. Once this first step is completed our purpose is to evaluate shielding requirements for such a device by preparing adequate phase space files. Methods: It is known that electron beam simulation parameters required for state-of-the-art Monte Carlo codes to obtain a good match with measured data, like the mean energy or the FWHM, may not be code-independent due to the different set of process simulated and formalisms involved. Then, to cross-check our results against any issue in the simulation we have compared experimental data (PDD and profiles for electrons in the range 4 to 12 MeV) with simulations performed independently using both Penelope2011 and Geant4 codes. To do so, the geometry and materials of the head of the accelerator have been fully characterized following information provided by the manufacturer. Results: Both simulations agree with experimental data within experimental uncertainties (±1 mm displacement), although small variations (less than 10%) in the mean energy and FWHM are required to match measured values depending on the code used. Conclusion: Independent Monte Carlo simulations were used to obtain an excellent match to measured electron dose distributions. This opens the road to use such data for evaluating shielding requirements which is the main objective of this project.

07 ISOTOPE AND RADIATION SOURCES↗